A randomized controlled non-inferiority trial examined lower dose prednisolone and activated vitamin D in adult minimal change podocytopathy.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Minimal change disease (MCD) is a frequent cause of nephrotic syndrome in adults.

Registered at ClinicalTrials.gov with study number NCT03210688.

Who Took Part

The abstract describes 67 adults taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

The adults were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

The primary endpoint was remission rate.

Secondary endpoints included time to remission, relapse rate, time to relapse, incidence of serious adverse events and glucocorticoid-related toxicity.

What Was Measured

Topics PubMed links to this paper include Prednisolone, Nephrosis, Lipoid, Remission Induction, Hydroxycholecalciferols, Glucocorticoids and Recurrence.

Author keywords: albuminuria, clinical study, glomerulonephritis and nephrotic syndrome.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Vitamin D, K2, Magnesium and Zinc in 67 adults.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Kidney international), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.